PhD candidate: modelling toxicity of hypo-fractionated radiotherapy for prostate cancer

We are looking for an enthusiastic researcher that is eager to collect and analyze clinical patient data with the ultimate purpose to improve our clinical patient care and help to answer the question: How should we create the best possible radiotherapy treatment plan with minimized risks of long-term side effects ?

In this PhD project we aim at developing adequate prediction models for toxicity risks after hypofractionated radiotherapy for prostate cancer, and translate these into optimal treatment solutions. Hypofractionation using advanced radiotherapy techniques and online imaging has become the new standard in radiotherapy for prostate cancer. At the same time, prediction models used for treatment optimization strategies are still unchanged and based on data collected with standard fractionation. To develop accurate models for the clinic will be of great importance to limit toxicity risks for each patient as much as possible. Data of an ongoing prospective cohort study will be used to develop these models; also data from other institutes will be used to validate these models.

You will work in a multi-disciplinary team of radiation oncologists, medical physicists, data managers, and translational researchers at a world leading university medical center. You will handle databases, help with documentation of side effects, analyze data, develop prediction models and investigate their impact on optimized dose, write and publish manuscripts, and report results at local meetings and at (inter-) national conferences.

This project, "Hypofractionated radiotherapy for prostate cancer: towards evidence-based best practice with state-of-the art normal tissue complication models - HYPROSTAR", is a collaboration between the Erasmus Medical Center and other Dutch radiotherapy institutes, and is funded by KWF (Dutch Cancer Society) for a period of 4 years.